Alnylam Pharmaceuticals
在场
是其中之一......
Alnylam Pharmaceuticals 是一家在股票代码 ALNY (US) 下上市的公司。
Alnylam Pharmaceuticals 在 2 个国家有直接业务。
高管
查看带有其 37 名主要高管的组织结构图
Alnylam Pharmaceuticals 搜索最多的简介
- Yvonne Greenstreet, Chief Executive Officer and Director
- Amy Schulman, Chairman of the Board
- Carolyn Bertozzi, Director
创建提醒
跟踪 Alnylam Pharmaceuticals 的高管变动
生物技术
Alnylam Pharmaceuticals 拥有 2,317 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- AgomAb Therapeutics 刚刚宣布为 89 筹款数百万美元。 (公布2024十月29号).
- Seaport Therapeutics 刚刚宣布为 225 筹款数百万美元。 (公布2024十月25号).
- TuHura Biosciences and Kintara Therapeutics have merged (公布2024十月20号)..
生物技术 行业的其他推荐联系人
消息
Alnylam Pharmaceuticals 的最新新闻稿
- Alnylam to Showcase Latest Data from TTR Franchise and Hypertension Program at American Heart Association Scie
- Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity
- Alnylam Submits Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Vutrisir
- Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis W
- Alnylam to Webcast TTR Investor Day
- Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with A
- Alnylam to Webcast Presentations at Upcoming September Investor Conferences
- Alnylam Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Period Activity
- Alnylam to Present Detailed Results from the HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amy
- Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Sign
- View more press releases Close
通过电子邮件
